Polymedco Cancer Diagnostic Products LLC

Polymedco Cancer Diagnostic Products LLC is a small disadvantaged business subsidiary of Polymedco LLC headquartered in Cortlandt Manor, New York, that specializes in providing clinical diagnostic products and comprehensive laboratory services focused on colorectal cancer screening and detection. The company is a critical supplier of fecal immunochemical testing (FIT) solutions, analyzers, reagents, and related diagnostic services to federal healthcare agencies, with a particular emphasis on serving the Department of Veterans Affairs across multiple Veterans Integrated Service Networks. Polymedco has established itself as an experienced federal contractor with an extensive portfolio of indefinite delivery contracts, blanket purchase agreements, and delivery orders valued in the millions of dollars, demonstrating sustained procurement relationships with federal agencies committed to cancer prevention and early detection initiatives.

Through its federal contract awards, Polymedco Cancer Diagnostic Products LLC has delivered an extensive range of fecal immunochemical testing products and services, including FDA-approved FIT collection kits, specialized analyzers such as the OC-Sensor Diana FIT Analyzer and PC-Auto Sensor Diana systems, reagents and consumables necessary for diagnostic testing, sampling bottles and mailers, laboratory testing services, equipment maintenance and calibration, technician training, and comprehensive technical support. The company's primary federal customer is the Department of Veterans Affairs, which has awarded numerous contracts across multiple Veterans Integrated Service Networks including VISN 1, 4, 5, 6, 8, 10, 17, 19, 21, 22, and 23, with these contracts supporting the VA's nationwide colorectal cancer screening initiatives for the veteran population. Additional federal customers include the Defense Health Agency, Indian Health Service, Bureau of Medicine and Surgery, and the Air Force Materiel Command, reflecting Polymedco's role as a trusted supplier across the federal healthcare ecosystem. The majority of Polymedco's contract awards have been issued without small business set-asides, indicating full and open competition, though several contracts carrying total small business set-aside designations have also been awarded, particularly through the Defense Health Agency. Contract values have ranged from modest purchase orders under $10,000 to significant delivery orders and blanket purchase agreement calls exceeding $500,000, with individual Indefinite Delivery Contracts reaching multi-million dollar ceiling values. Polymedco has consistently performed as a prime contractor on these awards, with performance occurring primarily at its Cortlandt Manor, New York headquarters facility, though some delivery orders have specified performance locations at various VA medical facilities and federal healthcare sites across the country.

Polymedco Cancer Diagnostic Products LLC currently holds multiple Indefinite Delivery Contract vehicles with substantial ceiling values and extended performance periods. The company's largest active IDC is a $5.355 million single-award Indefinite Delivery Contract with Veterans Integrated Service Network 17 for fecal immunochemical test kit mailing services, effective through January 14, 2030, which has generated multiple delivery orders to support FIT kit distribution across six distinct Veterans Health Care Systems within VISN 17. An additional $1.741 million Indefinite Delivery Contract with VISN 21 for fecal occult blood testing services and supplies is active through September 29, 2026, with multiple task orders issued for cost-per-test services across California, Nevada, and Hawaii facilities. Polymedco also maintains a $1 million IDC with VISN 17 for North Texas fecal occult blood testing services through September 30, 2028, a $666,160 IDC with VISN 8 for immunochemical fecal occult blood test reagents through May 12, 2030, and a $1,055,120 IDC with VISN 8 for comprehensive cancer screening products and services through March 31, 2030. The company holds several Blanket Purchase Agreement vehicles, including a $7.5 million single-award BPA with the Defense Health Agency for fecal immunochemical test kits, reagents, supplies, consumables, maintenance, calibration, training, and support services through September 7, 2030; a $494,650 BPA with VISN 17 for immunochemical fecal occult blood testing on a cost-per-test basis through September 30, 2026; and additional BPA vehicles with VISN 10 and VISN 19 valued at $249,160 and $249,466 respectively. These indefinite delivery vehicles and blanket purchase agreements establish Polymedco as an established supplier with authorized access to federal procurement, enabling efficient and standardized ordering of cancer screening diagnostics across the Veterans Health Administration and Defense Health Agency without requiring individual competitive procurements for each purchase or task order, thereby supporting the federal government's commitment to widespread colorectal cancer screening and prevention among veterans and military beneficiaries.